Dynavax Technologies Corporation (DVAX)
NASDAQ: DVAX · Real-Time Price · USD
10.88
-0.02 (-0.18%)
Apr 25, 2025, 12:06 PM EDT - Market open
Dynavax Technologies Revenue
In the year 2024, Dynavax Technologies had annual revenue of $277.25M with 19.36% growth. Dynavax Technologies had revenue of $72.03M in the quarter ending December 31, 2024, with 29.56% growth.
Revenue (ttm)
$277.25M
Revenue Growth
+19.36%
P/S Ratio
5.11
Revenue / Employee
$684,558
Employees
405
Market Cap
1.35B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 277.25M | 44.96M | 19.36% |
Dec 31, 2023 | 232.28M | -490.40M | -67.86% |
Dec 31, 2022 | 722.68M | 283.24M | 64.45% |
Dec 31, 2021 | 439.44M | 399.19M | 991.75% |
Dec 31, 2020 | 40.25M | 5.03M | 14.29% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
DVAX News
- 2 days ago - Dynavax to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025 - PRNewsWire
- 3 days ago - Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders - Business Wire
- 8 days ago - Dynavax Files Definitive Proxy Statement and Sends Letter to Stockholders - PRNewsWire
- 9 days ago - Deep Track Capital Comments on Dynavax Technologies' Rejection of Most Recent Settlement Offer - Business Wire
- 21 days ago - Dynavax Files Preliminary Proxy Statement - PRNewsWire
- 6 weeks ago - Deep Track Capital Sends Letter to Dynavax Technologies' Board of Directors - Business Wire
- 7 weeks ago - Dynavax Announces Convertible Debt Refinancing and Common Stock Share Repurchase - PRNewsWire
- 7 weeks ago - Dynavax Technologies: A Post-Earnings Assessment With Growing Market Share - Seeking Alpha